Ignite Creation Date:
2025-12-26 @ 4:02 PM
Ignite Modification Date:
2025-12-30 @ 5:36 AM
Study NCT ID:
NCT06615206
Status:
RECRUITING
Last Update Posted:
2024-11-26
First Post:
2024-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A First-in-Human Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of a Novel CRISPR RNA-editing Therapy in Patients with Mecp2 Duplication Syndrome, a Rare Orphan Disease (HERO)
Sponsor:
HuidaGene Therapeutics Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-10-30
Start Date Type:
ACTUAL
Primary Completion Date:
2026-10-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-04
First Submit QC Date:
None
Study First Post Date:
2024-09-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-22
Last Update Post Date:
2024-11-26
Last Update Post Date Type:
ACTUAL